185 related articles for article (PubMed ID: 34309232)
21. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.
Liao H; Bai Y; Qiu S; Zheng L; Huang L; Liu T; Wang X; Liu Y; Xu N; Yan X; Guo H
Oncotarget; 2015 Apr; 6(11):8914-28. PubMed ID: 25871397
[TBL] [Abstract][Full Text] [Related]
22. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
[TBL] [Abstract][Full Text] [Related]
23. Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B.
Lee Walmsley D; Murray JB; Dokurno P; Massey AJ; Benwell K; Fiumana A; Foloppe N; Ray S; Smith J; Surgenor AE; Edmonds T; Demarles D; Burbridge M; Cruzalegui F; Kotschy A; Hubbard RE
J Med Chem; 2021 Jul; 64(13):8971-8991. PubMed ID: 34143631
[TBL] [Abstract][Full Text] [Related]
24. CC-401 Promotes β-Cell Replication via Pleiotropic Consequences of DYRK1A/B Inhibition.
Abdolazimi Y; Zhao Z; Lee S; Xu H; Allegretti P; Horton TM; Yeh B; Moeller HP; Nichols RJ; McCutcheon D; Shalizi A; Smith M; Armstrong NA; Annes JP
Endocrinology; 2018 Sep; 159(9):3143-3157. PubMed ID: 29514186
[TBL] [Abstract][Full Text] [Related]
25. miR-143 inhibits oncogenic traits by degrading NUAK2 in glioblastoma.
Fu TG; Wang L; Li W; Li JZ; Li J
Int J Mol Med; 2016 Jun; 37(6):1627-35. PubMed ID: 27081712
[TBL] [Abstract][Full Text] [Related]
26. Estrogen-related receptor β activation and isoform shifting by cdc2-like kinase inhibition restricts migration and intracranial tumor growth in glioblastoma.
Tiek DM; Khatib SA; Trepicchio CJ; Heckler MM; Divekar SD; Sarkaria JN; Glasgow E; Riggins RB
FASEB J; 2019 Dec; 33(12):13476-13491. PubMed ID: 31570001
[TBL] [Abstract][Full Text] [Related]
27. Tumor-derived miR-378a-3p-containing extracellular vesicles promote osteolysis by activating the Dyrk1a/Nfatc1/Angptl2 axis for bone metastasis.
Wang J; Du X; Wang X; Xiao H; Jing N; Xue W; Dong B; Gao WQ; Fang YX
Cancer Lett; 2022 Feb; 526():76-90. PubMed ID: 34801597
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of TRPM7 by carvacrol suppresses glioblastoma cell proliferation, migration and invasion.
Chen WL; Barszczyk A; Turlova E; Deurloo M; Liu B; Yang BB; Rutka JT; Feng ZP; Sun HS
Oncotarget; 2015 Jun; 6(18):16321-40. PubMed ID: 25965832
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A.
Zhou Q; Reekie TA; Abbassi RH; Indurthi Venkata D; Font JS; Ryan RM; Munoz L; Kassiou M
Bioorg Med Chem; 2018 Dec; 26(22):5852-5869. PubMed ID: 30401502
[TBL] [Abstract][Full Text] [Related]
30. Regulation of RCAN1 protein activity by Dyrk1A protein-mediated phosphorylation.
Jung MS; Park JH; Ryu YS; Choi SH; Yoon SH; Kwen MY; Oh JY; Song WJ; Chung SH
J Biol Chem; 2011 Nov; 286(46):40401-12. PubMed ID: 21965663
[TBL] [Abstract][Full Text] [Related]
31. DYRK1A Controls HIV-1 Replication at a Transcriptional Level in an NFAT Dependent Manner.
Booiman T; Loukachov VV; van Dort KA; van 't Wout AB; Kootstra NA
PLoS One; 2015; 10(12):e0144229. PubMed ID: 26641855
[TBL] [Abstract][Full Text] [Related]
32. Selective inhibition of the kinase DYRK1A by targeting its folding process.
Kii I; Sumida Y; Goto T; Sonamoto R; Okuno Y; Yoshida S; Kato-Sumida T; Koike Y; Abe M; Nonaka Y; Ikura T; Ito N; Shibuya H; Hosoya T; Hagiwara M
Nat Commun; 2016 Apr; 7():11391. PubMed ID: 27102360
[TBL] [Abstract][Full Text] [Related]
33. FOXO1 associated with sensitivity to chemotherapy drugs and glial-mesenchymal transition in glioma.
Chen C; Han G; Li Y; Yue Z; Wang L; Liu J
J Cell Biochem; 2019 Jan; 120(1):882-893. PubMed ID: 30216501
[TBL] [Abstract][Full Text] [Related]
34. Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway.
Nakano I; Joshi K; Visnyei K; Hu B; Watanabe M; Lam D; Wexler E; Saigusa K; Nakamura Y; Laks DR; Mischel PS; Viapiano M; Kornblum HI
Neuro Oncol; 2011 Jun; 13(6):622-34. PubMed ID: 21558073
[TBL] [Abstract][Full Text] [Related]
35. Identification of a DYRK1A Inhibitor that Induces Degradation of the Target Kinase using Co-chaperone CDC37 fused with Luciferase nanoKAZ.
Sonamoto R; Kii I; Koike Y; Sumida Y; Kato-Sumida T; Okuno Y; Hosoya T; Hagiwara M
Sci Rep; 2015 Aug; 5():12728. PubMed ID: 26234946
[TBL] [Abstract][Full Text] [Related]
36. DYRK1A is a novel negative regulator of cardiomyocyte hypertrophy.
Kuhn C; Frank D; Will R; Jaschinski C; Frauen R; Katus HA; Frey N
J Biol Chem; 2009 Jun; 284(25):17320-17327. PubMed ID: 19372220
[TBL] [Abstract][Full Text] [Related]
37. Integrin-linked kinase (ILK) regulation of the cell viability in PTEN mutant glioblastoma and in vitro inhibition by the specific COX-2 inhibitor NS-398.
Obara S; Nakata M; Takeshima H; Katagiri H; Asano T; Oka Y; Maruyama I; Kuratsu J
Cancer Lett; 2004 May; 208(1):115-22. PubMed ID: 15105053
[TBL] [Abstract][Full Text] [Related]
38. Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.
Jarhad DB; Mashelkar KK; Kim HR; Noh M; Jeong LS
J Med Chem; 2018 Nov; 61(22):9791-9810. PubMed ID: 29985601
[TBL] [Abstract][Full Text] [Related]
39. A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition.
Kim H; Lee KS; Kim AK; Choi M; Choi K; Kang M; Chi SW; Lee MS; Lee JS; Lee SY; Song WJ; Yu K; Cho S
Dis Model Mech; 2016 Aug; 9(8):839-48. PubMed ID: 27483355
[TBL] [Abstract][Full Text] [Related]
40. Chronophin regulates active vitamin B6 levels and transcriptomic features of glioblastoma cell lines cultured under non-adherent, serum-free conditions.
Schulze M; Hutterer M; Sabo A; Hoja S; Lorenz J; Rothhammer-Hampl T; Herold-Mende C; Floßbach L; Monoranu C; Riemenschneider MJ
BMC Cancer; 2018 May; 18(1):524. PubMed ID: 29724193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
